Sign In
Buy FBRX
$17.00
-1.18 (-6.46%)
At Close: Jun 03, 2026
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
04:05pm, Friday, 17'th May 2024
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
04:05pm, Monday, 13'th May 2024
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
What Makes Forte Biosciences (FBRX) a New Buy Stock
01:01pm, Monday, 25'th Mar 2024
Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
04:05pm, Monday, 18'th Mar 2024
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
04:01pm, Friday, 01'st Dec 2023
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement aw
ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual Meeting
10:50am, Thursday, 14'th Sep 2023
NEW YORK--(BUSINESS WIRE)--Camac Partners, LLC (“Camac”) and ATG Capital Management, LLC (“ATG”) (together with the other participants in their solicitation, the “Concerned Stockholders,”
NEW YORK--(BUSINESS WIRE)--Camac Partners, LLC (“Camac”) and ATG Capital Management, LLC (“ATG”) (together with the other participants in their solicitation, the “Concerned Stockholders,”
Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders
08:00am, Friday, 25'th Aug 2023
NEW YORK--(BUSINESS WIRE)--Camac Partners, LLC (“Camac”) and ATG Capital Management, LLC (“ATG”) (together with the other participants in their solicitation, the “Concerned Stockholders,”
Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update
04:01pm, Monday, 14'th Aug 2023
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-detailed diseases, today announced second quarter
Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102
04:01pm, Tuesday, 01'st Aug 2023
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced key R&D updates for FB-102 and the clo
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
04:01pm, Friday, 19'th May 2023
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced the issuance of an equity inducement a
Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update
04:01pm, Monday, 15'th May 2023
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced first quarter 2023 results and provide
Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update
04:05pm, Friday, 31'st Mar 2023
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced full year 2022 results and provided a
Mr. David Gryska Appointed to Forte Biosciences Board of Directors
04:05pm, Thursday, 12'th Jan 2023
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), announced today that Mr. David Gryska has been appointed to the Forte Biosciences Board of Directors. Mr. Gryska w
Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update
04:01pm, Monday, 14'th Nov 2022
DALLAS--( BUSINESS WIRE )--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced third quarter 2022 results and provi
